Top

Published in:

01-10-2009 | Letter to the Editor

Two rare MPL gene mutations in patients with essential thrombocythemia

Authors: Haruhiko Ohashi, Kayoko Arita, Shoko Fukami, Kayo Oguri, Hirokazu Nagai, Toshiya Yokozawa, Tomomitsu Hotta, Shuichi Hanada

Published in: International Journal of Hematology | Issue 3/2009

Excerpt

In contrast to polycythemia vera, approximately half of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) are negative for JAK2-V617F [1]. Two missense mutations in Codon 515 of the thrombopoietin receptor (TpoR/MPL) gene (W515L and W515K) have been found in a small portion (1–9%) of ET and PMF patients [2‐4], and several other MPL exon 10 mutations have also been reported [5]. In the process of examining samples of 20 JAK2-V617F-negative ET patients for MPL mutations, other than three patients with W515K, we found two patients with sequence alterations that had not been reported in ET patients. …

Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008;22:1841–4.CrossRefPubMed

Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLOS Med. 2006;3:e270.CrossRefPubMedPubMedCentral

Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.CrossRefPubMed

Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141–9.CrossRefPubMed

Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8):1557–66.CrossRefPubMed

Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane–cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107:1864–71.CrossRefPubMedPubMedCentral

Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198–200.CrossRefPubMed

Title: Two rare MPL gene mutations in patients with essential thrombocythemia
Authors: Haruhiko Ohashi
Kayoko Arita
Shoko Fukami
Kayo Oguri
Hirokazu Nagai
Toshiya Yokozawa
Tomomitsu Hotta
Shuichi Hanada
Publication date: 01-10-2009
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-009-0413-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2009

Plasma cell leukemia producing monoclonal immunoglobulin E

Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity

Long-term culture of leukemic bone marrow primary cells in biomimetic osteoblast niche

Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD

National questionnaire survey of TMA

Expression of annexin II in experimental abdominal aortic aneurysms

Keynote webinar | Spotlight on antibody–drug conjugates in cancer